



Corrigendum: 7-Ethyl-10-Hydroxycamptothecin, A DNA Topoisomerase I Inhibitor, Performs BRD4 Inhibitory Activity and Inhibits Human Leukemic Cell Growth

Airong Wang, Lingling Li, Mengya Li, Shujuan Wang and Chong Wang*

Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Keywords: SN-38, BRD4, inhibitor, leukemic cell, growth

A Corrigendum on

7-Ethyl-10-Hydroxycamptothecin, A DNA Topoisomerase I Inhibitor, Performs BRD4 Inhibitory Activity and Inhibits Human Leukemic Cell Growth

by Wang, A., Li, L., Li, M., Wang, S., and Wang, C. (2021). Front. Pharmacol. 10:757060. doi: 10.3389/fphar.2021.664176

orial Office, Switzerland In the original article, the title was incorrectly written as "Case Report: 7-Ethyl-10-

hydroxycamptothecin, a DNA topoisomerase I inhibitor, performs BRD4 inhibitory activity and inhibits human leukemic cell growth.

The correct article title is "7-Ethyl-10-hydroxycamptothecin, a DNA topoisomerase I inhibitor, performs BRD4 inhibitory activity and inhibits human leukemic cell growth".

The authors state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Wang, Li, Li, Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

OPEN ACCESS

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

*Correspondence:

Chong Wang fccwangc@zzu.edu.cn

Specialty section:

This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology

> Received: 11 August 2021 Accepted: 13 August 2021 Published: 30 August 2021

Citation:

Wang A, Li L, Li M, Wang S and Wang C (2021) Corrigendum: 7-Ethyl-10-Hydroxycamptothecin, A DNA Topoisomerase I Inhibitor, Performs BRD4 Inhibitory Activity and Inhibits Human Leukemic Cell Growth. Front. Pharmacol. 12:757060. doi: 10.3389/fphar.2021.757060